NGAM Advisors L.P. Decreases Position in Core Laboratories N.V. (NYSE:CLB)

NGAM Advisors L.P. decreased its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 3.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 164,869 shares of the oil and gas company’s stock after selling 6,582 shares during the period. NGAM Advisors L.P. owned approximately 0.37% of Core Laboratories N.V. worth $16,696,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Gulf International Bank UK Ltd increased its stake in shares of Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Core Laboratories N.V. by 156.2% in the first quarter. Goldman Sachs Group Inc. now owns 68,823 shares of the oil and gas company’s stock worth $7,951,000 after buying an additional 41,955 shares during the period. BTIM Corp. raised its stake in shares of Core Laboratories N.V. by 6.3% in the first quarter. BTIM Corp. now owns 77,224 shares of the oil and gas company’s stock worth $8,921,000 after buying an additional 4,544 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Core Laboratories N.V. by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 217,670 shares of the oil and gas company’s stock worth $26,128,000 after buying an additional 6,962 shares during the period. Finally, Morgan Stanley raised its stake in shares of Core Laboratories N.V. by 17.5% in the first quarter. Morgan Stanley now owns 167,465 shares of the oil and gas company’s stock worth $19,346,000 after buying an additional 24,929 shares during the period.

Shares of Core Laboratories N.V. (CLB) opened at 89.55 on Friday. The company has a 50 day moving average price of $100.15 and a 200 day moving average price of $107.78. Core Laboratories N.V. has a 52 week low of $87.83 and a 52 week high of $125.83. The company has a market capitalization of $3.95 billion, a PE ratio of 54.94 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last announced its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.01. The firm had revenue of $163.90 million during the quarter, compared to analysts’ expectations of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.35 earnings per share. On average, equities research analysts expect that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 14th. Shareholders of record on Monday, July 17th were paid a $0.55 dividend. The ex-dividend date of this dividend was Thursday, July 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.46%. Core Laboratories N.V.’s payout ratio is currently 134.15%.

COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/08/19/ngam-advisors-l-p-sells-6582-shares-of-core-laboratories-n-v-nyseclb-updated-updated.html.

A number of analysts have recently commented on the company. BidaskClub lowered Core Laboratories N.V. from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. Morgan Stanley lowered their target price on Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. ValuEngine raised Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Citigroup Inc. lowered their target price on Core Laboratories N.V. from $102.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 26th. Finally, UBS AG reaffirmed a “neutral” rating and issued a $110.00 target price (down previously from $125.00) on shares of Core Laboratories N.V. in a research report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

What are top analysts saying about Core Laboratories N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Core Laboratories N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit